An additional important feature shared by PRO and BRY is the potential to inhibit de novo infection by reactivated virus through the capacity to downregulate the HIV-1 receptor CD4 as well as CCR5 and/or CXCR4 co-receptors (46, 58, 59). The gene discussed is CD4; the disease is infection.